semaglutide compound lawsuit Hims & Hers Health will stop selling GLP-1 to settle Novo faces investor lawsuit over
Description
What did the pivotal Phase 3 obesity trial show
Nonfatal myocardial infarction occurred in 2.3% of patients treated with oral semaglutide and 1.9% treated with placebo (HR 1.18, 95% CI 0.731.90), nonfatal stroke occurred in 0.8% versus 1.0% treated with placebo (HR 0.74, 95% CI 0.351.57), and death from cardiovascular causes occurred in 0.9% versus 1.9% treated with placebo (HR 0.51, 95% CI 0.310.84)
They are classified as a 'common' side effect, affecting between 1 and 10 users in 100
Feet : Toe joints on one or both feet may be swollen and tender to touch
Average appetite score for the week: Compare to previous weeks
Many patients notice reduced appetite within weeks, with gradual, sustainable results over several months.
